The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation.

Song Hee KimWon Hyeok LeeDaseul SeongJae Hee AnHyoung Uk JeHae Yun NamSang Yoon KimSeong Who KimMyung Woul Han

Published in: Head & neck (2019)

Our results suggest that CIP2A may serve as a therapeutic target of rapamycin through induction of senescence in radioresistant HNC with TP53 mutation.

Keyphrases

dna damage
endothelial cells